Page 65 - GTM-1-1

Global Translational Medicine Fusion events identified in tumor

51. Wang X, Qiao Y, Asangani IA, et al., 2017, Development of https://doi.org/10.1038/ng.2611
peptidomimetic inhibitors of the ERG gene fusion product 63. Weinberg F, Griffin R, Frohlich M, et al., 2020, Identification
in prostate cancer. Cancer Cell, 31(4): 532–548.e537.
and characterization of a BRAF fusion oncoprotein with
https://doi.org/10.1016/j.ccell.2017.02.017 retained autoinhibitory domains. Oncogene, 39(4): 814–832.
52. Camidge DR, Dziadziuszko R, Peters S, et al., 2019, Updated https://doi.org/10.1038/s41388-019-1021-1
efficacy and safety data and impact of the EML4-ALK fusion 64. Fangusaro J, Onar-Thomas A, Poussaint TY, et al., 2019,
variant on the efficacy of alectinib in untreated ALK-positive Selumetinib in paediatric patients with BRAF-aberrant or
advanced non-small cell lung cancer in the global phase III neurofibromatosis Type 1-associated recurrent, refractory,
ALEX study. J Thorac Oncol, 14(7): 1233–1243.
or progressive low-grade glioma: A multicentre, phase 2
https://doi.org/10.1016/j.jtho.2019.03.007 trial. Lancet Oncol, 20(7): 1011–1022.
53. Gong J, Gregg JP, Ma W, et al., 2019, Squamous cell https://doi.org/10.1016/s1470-2045(19)30277-3
transformation of primary lung adenocarcinoma in a 65. Sievert AJ, Lang SS, Boucher KL, et al., 2013, Paradoxical
patient with EML4-ALK fusion variant 5 refractory to ALK activation and RAF inhibitor resistance of BRAF protein
inhibitors. J Natl Compr Canc Netw, 17(4): 297–301.
kinase fusions characterizing pediatric astrocytomas. Proc
https://doi.org/10.6004/jnccn.2019.7291 Natl Acad Sci U S A, 110(15): 5957–5962.
54. Kohsaka S, Hayashi T, Nagano M, et al., 2020, Identification https://doi.org/10.1073/pnas.1307863110
of Novel CD74-NRG2alpha fusion from comprehensive 66. Lawrence MS, Stojanov P, Mermel CH, et al., 2014, Discovery
profiling of lung adenocarcinoma in Japanese never or light and saturation analysis of cancer genes across 21 tumour
smokers. J Thorac Oncol, 15(6): 948–961.
types. Nature, 505(7484): 495–501.
https://doi.org/10.1016/j.jtho.2020.01.021
https://doi.org/10.1038/nature12912
55. Jerby-Arnon L, Neftel C, Shore ME, et al., 2021, Opposing 67. Hallberg B, Palmer RH, 2016, The role of the ALK receptor
immune and genetic mechanisms shape oncogenic
programs in synovial sarcoma. Nat Med, 27: 289–300. in cancer biology. Ann Oncol, 27 Suppl 3: iii4–iii15.
https://doi.org/10.1093/annonc/mdw301
56. Karajannis MA, Legault G, Fisher MJ, et al., 201, Phase II
study of sorafenib in children with recurrent or progressive 68. Childress MA, Himmelberg SM, Chen H, et al., 2018,
low-grade astrocytomas. Neuro Oncol, 16(10): 1408–1416. ALK fusion partners impact response to ALK inhibition:
Differential effects on sensitivity, cellular phenotypes, and
https://doi.org/10.1093/neuonc/nou059
biochemical properties. Mol Cancer Res, 16(11): 1724–1736.
57. Helgager J, Lidov HG, Mahadevan NR, et al., 2017, A novel
GIT2-BRAF fusion in pilocytic astrocytoma. Diagn Pathol, https://doi.org/10.1158/1541-7786.mcr-18-0171
12(1): 82. 69. Soda M, Takada S, Takeuchi K, et al., 2008, A mouse model
for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S
https://doi.org/10.1186/s13000-017-0669-5
A, 105(50): 19893–19897.
58. Jones DT, Hutter B, Jager N, et al., 2013, Recurrent somatic
alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. https://doi.org/10.1073/pnas.0805381105
Nat Genet, 45(8): 927–932. 70. Clarke M, Mackay A, Ismer B, et al., 2020, Infant high-
grade gliomas comprise multiple subgroups characterized
59. Qaddoumi I, Orisme W, Wen J, et al., 2016, Genetic alterations
in uncommon low-grade neuroepithelial tumors: BRAF, by novel targetable gene fusions and favorable outcomes.
FGFR1, and MYB mutations occur at high frequency and Cancer Discov, 10(7): 942–963.
align with morphology. Acta Neuropathol, 131(6): 833–845. 71. Nguyen KT, Zong CS, Uttamsingh S, et al., 2002, The role
of phosphatidylinositol 3-kinase, rho family GTPases, and
https://doi.org/10.1093/neuonc/now075.10
STAT3 in Ros-induced cell transformation. J Biol Chem,
60. Ryall S, Zapotocky M, Fukuoka K, et al., 2020, Integrated 277(13): 11107–11115.
molecular and clinical analysis of 1,000 pediatric low-grade
gliomas. Cancer Cell, 37(4): 569–583.e565. https://doi.org/10.1074/jbc.m108166200
72. Charest A, Kheifets V, Park J, et al., Oncogenic targeting
61. Tomic TT, Olausson J, Wilzen A, et al., 2017, A new GTF2I-
BRAF fusion mediating MAPK pathway activation in of an activated tyrosine kinase to the Golgi apparatus in a
pilocytic astrocytoma. PLoS One, 12(4): e0175638. glioblastoma. Proc Natl Acad Sci U S A, 100(3): 916–921.
https://doi.org/10.1073/pnas.242741799
https://doi.org/10.1371/journal.pone.0175638
73. Uguen A, De Braekeleer M, 2016, ROS1 fusions in cancer:
62. Zhang J, Wu G, Miller CP, et al., 2013, Whole-genome
sequencing identifies genetic alterations in pediatric low- A review. Future Oncol, 12(16): 1911–1928.
grade gliomas. Nat Genet, 45(6): 602–612. https://doi.org/10.2217/fon-2016-0050

Volume 1 Issue 1 (2022) 10 https://doi.org/10.36922/gtm.v1i1.54